Safety (local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse and serious experiences) Throughout study [clinicaltrials_resource:41aa6c9f3bda6205fd912c5d849c0f88]
One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Safety (local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse and serious experiences) Throughout study [clinicaltrials_resource:41aa6c9f3bda6205fd912c5d849c0f88]
One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
Bio2RDF identifier
41aa6c9f3bda6205fd912c5d849c0f88
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:41aa6c9f3bda6205fd912c5d849c0f88
measure [clinicaltrials_vocabulary:measure]
Safety (local and systemic rea ...... verse and serious experiences)
time frame [clinicaltrials_vocabulary:time-frame]
Throughout study
description
One 0.3 mg dose of DNA HIV vac ...... A or placebo at Months 4 and 6
identifier
clinicaltrials_resource:41aa6c9f3bda6205fd912c5d849c0f88
title
Safety (local and systemic rea ...... experiences) Throughout study
@en
type
label
Safety (local and systemic rea ...... a6c9f3bda6205fd912c5d849c0f88]
@en